STOCK TITAN

BIOMERICA INC - BMRA STOCK NEWS

Welcome to our dedicated page for BIOMERICA news (Ticker: BMRA), a resource for investors and traders seeking the latest updates and insights on BIOMERICA stock.

Biomerica Inc. (NASDAQ: BMRA) is a global biomedical technology company that specializes in developing, manufacturing, and marketing advanced diagnostic and therapeutic products for early detection and monitoring of chronic diseases. These products are used at the point-of-care, such as in homes and physicians’ offices, as well as in hospital and clinical laboratories.

The company's primary focus is on gastrointestinal diseases, food intolerances, diabetes, and esoteric testing. Biomerica’s flagship product, the inFoods® IBS, helps identify specific foods that, when eliminated, can relieve symptoms of irritable bowel syndrome (IBS). This diagnostic-guided therapy aims to provide a personalized dietary regimen for improved IBS management.

Another significant product is the Hp Detect™ Stool Antigen ELISA test, which recently received FDA 510(k) clearance. This test detects the presence of the H. pylori bacteria, a pathogen that infects approximately 35% of the U.S. population and is linked to gastric cancer, the third most common cause of cancer-related deaths worldwide. The test offers a reliable solution for diagnosing and assessing H. pylori infection status post-treatment.

Biomerica operates mainly in one segment: the development, marketing, and sales of diagnostic kits. The company has made notable achievements, such as receiving FDA clearances and forming partnerships with esteemed institutions like the University of Michigan. Their latest developments and news include presenting data on inFoods IBS technology at the 2024 Digestive Disease Week (DDW) Conference and appointing Jack Kenny, a seasoned healthcare executive, as the Chairman of the Board of Directors.

In terms of financial health, Biomerica generates the majority of its revenue from the European market. The company is committed to reducing healthcare costs while ensuring that their products enhance health and well-being. Their innovative approaches and strategic leadership aim to make significant advancements in the medical diagnostic industry.

Rhea-AI Summary
Biomerica, Inc. reported a 10.3% increase in revenues excluding Covid test sales for the second fiscal quarter of 2024 compared to the same period in 2023. The loss per share narrowed to $0.09 from $0.12 due to disciplined operating expense management. The company also received US FDA 510(k) clearance for its Hp Detect™ ELISA Test Product designed to detect the presence of the H. pylori bacteria, which infects approximately 35% of the U.S. population. The product is marketed to clinical labs in the US and internationally. The company also expanded its reach with the addition of new GI groups. The financial results for the second quarter of fiscal 2024 showed a 6.7% increase in net sales compared to the same period in 2023, with a 20.7% gross margin. Operating expenses improved to $1.9 million from $2.0 million in the prior year, and the company had cash and equivalents of $7.1 million as of November 30, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.13%
Tags
-
Rhea-AI Summary
Biomerica, Inc. (BMRA) has received FDA 510(k) clearance for its Hp Detect™ Stool Antigen ELISA test to detect H. pylori bacteria, which infects 35% of the U.S. population. The test can diagnose H. pylori presence, crucial for assessing status after treatment, especially in the context of increasing antibiotic resistance. Over 80% of gastric cancers are attributed to H. pylori infection, making this FDA clearance a milestone in providing a diagnostic solution for over 115 million people suffering from H. pylori infection across the U.S.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
66.67%
Tags
-
Rhea-AI Summary
Biomerica, Inc. (BMRA) to participate in 14th Annual Craig-Hallum Alpha Select Conference on November 16, 2023, in New York City. CEO Zackary Irani to host one-on-one and small group meetings.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.4%
Tags
conferences
Rhea-AI Summary
Biomerica (BMRA) remains on track for inFoods® IBS national rollout in 2024, expecting strong product revenue growth. New GI groups have signed up for the inFoods IBS product, demonstrating growing recognition and adoption in the medical community, positioning the company for growth. Clinical trials have shown significant improvement in IBS patients using the product, with notable outcomes comparable to FDA cleared drugs.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.59%
Tags
none
-
Rhea-AI Summary
Biomerica reports Q1 2024 financial results, with a 16.3% increase in revenues excluding Covid test sales. Company expects profitability with current cash position and forecasted revenue growth.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.33%
Tags
-
Rhea-AI Summary
Biomerica reports financial results for Q1 fiscal 2024
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.33%
Tags
Rhea-AI Summary
Dubai government approves insurance reimbursement for Biomerica's EZ Detect colorectal disease at-home screening test
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.68%
Tags
none
-
Rhea-AI Summary
Biomerica appoints Jack Kenny, former CEO of Meridian Bioscience, to its Board of Directors. Meridian Biosciences was acquired for $1.53 billion. Kenny's industry insights will be invaluable in launching inFoods IBS. His leadership at Meridian drove outstanding growth.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.35%
Tags
management
-
Rhea-AI Summary
Biomerica reports fiscal 2023 financial results, with net sales of $5.3M compared to $18.9M in fiscal 2022. Net loss was $7.1M for fiscal 2023. Revenues excluding Covid test sales increased by 15% for fiscal 2023. Successful completion of inFoods IBS pilot program with Gastrointestinal physician group. On track for national launch by Q1 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.35%
Tags
Rhea-AI Summary
CVS Pharmacy begins selling Biomerica's EZ Detect colorectal disease screening test in over 7,000 stores nationwide, projected to be on shelves in September.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
13.01%
Tags
none

FAQ

What is the current stock price of BIOMERICA (BMRA)?

The current stock price of BIOMERICA (BMRA) is $0.303 as of September 13, 2024.

What is the market cap of BIOMERICA (BMRA)?

The market cap of BIOMERICA (BMRA) is approximately 5.2M.

What does Biomerica Inc. specialize in?

Biomerica Inc. specializes in developing, manufacturing, and marketing advanced diagnostic products for the early detection and monitoring of chronic diseases.

What are the primary focus areas of Biomerica's products?

Biomerica primarily focuses on gastrointestinal diseases, food intolerances, diabetes, and esoteric testing.

What is the inFoods® IBS product?

The inFoods® IBS product is a diagnostic-guided therapy that identifies specific foods which, when eliminated, can alleviate IBS symptoms. It provides a personalized dietary regimen for improved IBS management.

What recent FDA clearance has Biomerica received?

Biomerica recently received FDA 510(k) clearance for its Hp Detect™ Stool Antigen ELISA test, designed to detect H. pylori bacteria.

What is the significance of the Hp Detect™ test?

The Hp Detect™ test helps diagnose H. pylori infection, which is linked to gastric cancer and affects approximately 35% of the U.S. population.

Where does Biomerica generate most of its revenue?

Biomerica generates the majority of its revenue from the European market.

Who is the new Chairman of the Board of Directors at Biomerica?

Jack Kenny, a former CEO of Meridian Bioscience, Inc., is the new Chairman of the Board of Directors at Biomerica.

What recent collaboration has Biomerica been involved in?

Biomerica has collaborated with the University of Michigan, and their data will be presented at the 2024 Digestive Disease Week (DDW) Annual Meeting.

How does Biomerica aim to reduce healthcare costs?

Biomerica's products are designed to enhance health and well-being while reducing total healthcare costs through early detection and monitoring of diseases.

What are some key advantages of Biomerica's Hp Detect™ test?

The Hp Detect™ test is highly accurate and offers several key advantages for laboratories, physicians, and patients, including an efficient, low-cost manufacturing process.

BIOMERICA INC

Nasdaq:BMRA

BMRA Rankings

BMRA Stock Data

5.21M
16.82M
7.3%
17.65%
0.43%
Medical Devices
In Vitro & in Vivo Diagnostic Substances
Link
United States of America
IRVINE